Glucagon-like peptide-1 receptor agonists (e.g., semaglutide and liraglutide) (GLP-1 RA) were first approved by the Food and Drug Administration (FDA) in 2005 for the treatment of Type 2 Diabetes but have only recently revolutionized the market as a weight loss drug for the non-diabetic patient. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.